Mark Steiner, MD
Cardiovascular Disease · Orlando, FLNPI 1023012093
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Medtronic at 45.5% of the total. 2025 is the largest year on record at $14,267, 9.3 times the $1,531 reported in 2019. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 634 payments — averaging $51.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Cardiovascular Systems Inc.$5K
- Abiomed$3K
- Boston Scientific$2K
- Shockwave Medical, Inc$1K
- Kestra Medical Technology Services, Inc.$956
- plus $6K from 32 others
Across 10 payments — averaging $2204.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$19K
- EKOS Corporation$3K
What the payments were for
- Speaking & faculty fees$13,93143%
- Travel & lodging$6322%
- Food & beverage$17,62754%
- Gifts$2371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 259 | $14,767 |
| Cardiovascular Systems Inc. | 53 | $4,909 |
| Abiomed | 81 | $3,075 |
| Boston Scientific | 41 | $1,666 |
| Shockwave Medical, Inc | 12 | $1,271 |
| Kestra Medical Technology Services, Inc. | 8 | $956 |
| E.r. Squibb & Sons, L.L.C. | 17 | $527 |
| Abbott | 16 | $526 |
| Johnson & Johnson | 8 | $509 |
| Amgen | 24 | $508 |
| AstraZeneca | 10 | $503 |
| W. L. Gore & Associates, Inc. | 8 | $353 |
| Teleflex LLC | 6 | $320 |
| Novartis | 17 | $314 |
| Penumbra, Inc. | 7 | $226 |
| Boehringer Ingelheim | 6 | $207 |
| Cvrx, Inc. | 3 | $205 |
| Pfizer | 12 | $188 |
| Esperion Therapeutics, Inc. | 4 | $159 |
| Biosense Webster, Inc. | 6 | $159 |
| Impulse Dynamics (USA) Inc. | 2 | $147 |
| Cardiva Medical, Inc. | 2 | $124 |
| Stryker | 1 | $117 |
| Alnylam Pharmaceuticals Inc. | 2 | $114 |
| Novo Nordisk | 5 | $103 |
| Inari Medical, Inc. | 3 | $95 |
| Atricure, Inc. | 2 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $55 |
| Cordis US CORP. | 2 | $37 |
| Cook Medical LLC | 1 | $36 |
| Livanova USA, Inc. | 2 | $31 |
| EKOS Corporation | 2 | $30 |
| Terumo Medical Corporation | 2 | $29 |
| Edwards Lifesciences | 1 | $26 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$9,754
- Diamondback Coronary$3,600
- Impella$1,134
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$708
- Assure WCD$693
- XARELTO$459
- RESOLUTE ONYX$415
- WATCHMAN Access System$301
- Repatha$251
- CAMZYOS$223
- CoreValve Evolut$165
- Penumbra System$153
- COREVALVE EVOLUT R$152
- Barostim Neo System$146
- CARDIOMEMS$145
- VenaSeal$140
- VIABAHN VBX Balloon Expandable Endoprosthesis$137
- OPTIMIZER$131
- WAINUA$129
- Vascular Lithotripsy$128
How this compares
$32,428 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 283 | $341,798 |
| EntrestoSacubitril/Valsartan | 71 | $110,363 |
| Repatha SureclickEvolocumab | 68 | $66,983 |
| XareltoRivaroxaban | 51 | $52,821 |
| MultaqDronedarone Hcl | 20 | $44,547 |
| JardianceEmpagliflozin | 36 | $37,741 |
| BrilintaTicagrelor | 33 | $33,001 |
| Ranolazine ErRanolazine | 59 | $7,121 |
| ClopidogrelClopidogrel Bisulfate | 375 | $4,900 |
| Metoprolol Succinate | 301 | $4,602 |
| Rosuvastatin Calcium | 273 | $3,532 |
| Ezetimibe | 109 | $2,913 |
| Losartan Potassium | 279 | $2,285 |
| Atorvastatin Calcium | 239 | $2,191 |
| Nitroglycerin | 50 | $2,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $188 | $341,798283 claims |
| NovartisEntresto | $314 | $110,36371 claims |
| Johnson & JohnsonXarelto | $509 | $52,82151 claims |
| Boehringer IngelheimJardiance | $207 | $37,74136 claims |
| AstraZenecaBrilinta | $503 | $33,00133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Orlando
- Rohit BhathejaOrlando$257K
- Nirav RavalOrlando$176K
- James TarverOrlando$112K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.